Hall's concern that there may be some potential confusion regarding the features of Retisert compared with those of Iluvien Ò (fluocinolone acetonide intravitreal implant) 0.19 mg, as they both contain fluocinolone acetonide as the active ingredient, and we are in support of a letter outlining their differences [2] .
However, we disagree with the promotional implication that Iluvien is an ''improvement'' over Retisert as there are no head-to-head clinical trials comparing these two products to merit that claim. Indeed, in addition to the approval for treatment of chronic non-infectious posterior uveitis, clinical studies have shown Retisert to be effective in reducing diabetic macular edema (DME) and improving visual acuity in patients with DME [3] . Retisert has also shown efficacy in the management of macular edema secondary to retinal vein occlusion in small studies [4, 5] . However, as Dr. Hall correctly stated, Retisert is not approved either in the US or in Europe for these latter indications. 
